TECH · 10-Q/A · 2026Q3 · Full report
Restructuring Charges
BIO-TECHNE Corp · 2026-11-12 · Importance 33 · Surprise 42 · In source text
Fiscal 2026 restructuring actions focused on streamlining brand architecture and realigning brand-support functions, including operations and personnel; the Company expects related costs through fiscal 2027. Costs recorded in the quarter ended September 30, 2026 were $2.258 million, including $1.996 million of corporate asset-related and other costs. Earlier actions to optimize global manufacturing included the Exosome Diagnostics business, for which Bio-Techne recorded a cumulative $83.1 million impairment in fiscal 2025. In September 2025, Bio-Techne agreed to sell that business for approximately $15.0 million, including approximately $6.8 million in stock at closing, and received a note payable in four annual $2.5 million installments through September 2029.
Key facts
- In the fourth quarter, Bio-Techne began restructuring activities to streamline brand architecture and realign brand-supporting functions, including operations and people; costs are expected through fiscal 2027 and will be recorded when specified criteria are met. source
- Bio-Techne recorded a cumulative $83.1 million impairment charge in fiscal 2025 related to assets and liabilities of its Exosome Diagnostics business classified as held-for-sale. source
- In the quarter ended September 30, 2025, Bio-Techne recognized a $6.8 million recovery of assets held-for-sale in selling, general and administrative expenses. source
- Fiscal 2025 restructuring actions targeted global manufacturing processes, including adjusting manufacturing locations and protocols to better align products with geographical and customer demand; related costs are expected through fiscal 2027. source
- BIO-TECHNE reported $3.838 million in restructuring and restructuring-related costs for the quarter ended September 30, 2026. source
- Bio-Techne recorded $2.258 million of restructuring and restructuring-related costs in the quarter ended September 30, 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | probable | — | In the fourth quarter, Bio-Techne began restructuring activities to streamline brand architecture and realign brand-supporting functions,… |